Amplia Therapeutics Ltd
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company.
The business
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Small Caps Research
No research on Amplia Therapeutics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise ATX based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Amplia Therapeutics Releases New Topline Data from ACCENT Narmafotinib Pancreatic Cancer Trial
Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced pancreatic cancer. The ACCENT clinical trial is investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of narmafotinib when used in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Latest data to 20 July has […]
Amplia Therapeutics achieves second complete response with narmafotinib in pancreatic cancer trial
Amplia Therapeutics (ASX: ATX) continues to make excellent progress with focal adhesion kinase (FAK) inhibitor narmafotinib, its best-in-class drug candidate for pancreatic cancer. New data from the company’s ongoing ACCENT trial investigating narmafotinib has further confirmed its potential. After Amplia’s announcement earlier this week that a separate patient had achieved a pathological complete response (CR) […]
Amplia Therapeutics reports first pathological complete response in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX: ATX) has recorded the first pathological complete response (pCR) from a patient participating in the company’s ongoing ACCENT clinical trial to treat metastatic pancreatic cancer. The trial is investigating the company’s best-in-class FAK (focal adhesion kinase) inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. The patient recorded a pCR after […]
Amplia Therapeutics allocated FDA fast-tracking for pancreatic cancer drug narmafotinib
Melbourne-based Amplia Therapeutics (ASX: ATX) has been granted Fast Track Designation for its narmafotinib advanced pancreatic cancer treatment candidate by the US Food and Drug Administration (FDA). Narmafotinib is the company’s best-in-class inhibitor of the focal adhesion kinase protein (FAK), which is over-expressed in pancreatic and other cancers and a drug target gaining increasing attention […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.